HCM News and Press, HUTCHMED (China) Limited From 08/01/22

Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE ® , SULANDA ® and ORPATHYS ® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO ...

Hutchmed (China) ( NASDAQ: HCM ) said it began dosing in a phase 2 bridging study of tazemetostat in China to treat patients with relapsed/refractory follicular lymphoma (R/R FL). Tazemetostat is developed by Epizyme ( NASDAQ: EPZM ) and Hutchmed has an ag...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a bridging study of tazemetostat in China. The first patient received th...

Paylocity is a provider of payroll and human capital management, or HCM, solutions servicing small- to mid-size clients in the United States. Overall, I think that Paylocity has a robust solution that could effectively compete in the fierce competition. Other competitors with more...

Hutchmed (China) ( NASDAQ: HCM ) said it began a phase 1 trial of HMPL-A83 in patients with advanced malignant neoplasms in China. The first patient received their first dose on July 15. The phase 1 study will evaluate the safety and preliminary efficacy ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a Phase I trial in China of HMPL-A83, an investigational novel Ig...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces the first presentation of results from the ongoing SAVANNAH global Phase II trial at the upcoming Inter...

Inmagene Biopharmaceuticals and Hutchmed (China) (​HCM) said the first person, based in Australia, was dosed in a global phase 1 trial of IMG-007 to treat  adult patients with moderate to severe atopic dermatitis (eczema). The early-stage trial is a ...

SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (" Inmagene ") and HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, bas...

France's Ipsen (OTCPK:IPSEY) (OTCPK:IPSEF) is acquiring Cambridge, Mass.-based cancer drug maker Epizyme (NASDAQ:EPZM) for $247M plus contingent value right (CVR). Ipsen will begin an all-cash tender offer to acquire all outstanding shares of Epizyme (EPZM) for $1.45/share plus a CV...